Claims
- 1. A pharmaceutical composition comprising an effective amount of a combination of a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist, or a 8 salt, enantiomer or prodrug form of the said agonist and/or antagonist, and optionally a pharmaceutically acceptable carrier.
- 2. The pharmaceutical composition according to claim 1, wherein the 5-HT2C receptor agonist has a selectivity for the 5-HT2C receptor of at least about 10, relative to the 5-HT2A receptor, the 5-HT2B receptor, and the 5-HT6 receptor, respectively.
- 3. The pharmaceutical composition according to claim 1 or 2, wherein the 5-HT6 receptor antagonist has a selectivity for the 5-HT6 receptor of at least about 10, relative to the 5-HT2A receptor, the 5-HT2B receptor and the 5-HT2C receptor, respectively.
- 4. The pharmaceutical composition according to claim 1, wherein the 5-HT2C receptor agonist is an arylpiperazine compound, such as a piperazinylpyrazine compound.
- 5. The pharmaceutical composition according to claim 1, wherein the 5-HT6 receptor antagonist is selected from azepinoindoles, such as arylsulfone-substituted hexahydroazepinoindoles, and arylsulfonylindoles.
- 6. A process for preparing a pharmaceutical composition according to claim 1, wherein a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist in a combined therapeutic amount are intimately mixed with a pharmaceutically acceptable carrier.
- 7. A kit comprising a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist as a combined preparation for simultaneous, separate or sequential use in therapy of a disease related to the 5-HT2C receptor and the 5-HT6 receptor.
- 8. The product according to claim 7, wherein the disease is selected from eating disorders, CNS disorders, urinary incontinence and glaucoma.
- 9. The product according to claim 8, wherein the disease is over-weight or obesity.
- 10. A method of treating a disease related to the 5-HT2C receptor and the 5-HT6 receptor, comprising administering to a human or animal subject in need thereof a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist in sufficient amounts to provide a therapeutic effect.
- 11. The method according to claim 10, wherein the disease is selected from eating disorders, CNS disorders, urinary incontinence and glaucoma.
- 12. The method according to claim 11, wherein the disease is over-weight or obesity.
- 13. The method according to claim 10, 11 or 12, wherein the 5-HT2C receptor agonist and the 5-HT6 receptor antagonist are administered as a combined pharmaceutical composition.
- 14. The pharmaceutical composition according to claim 2, wherein the 5-HT2C receptor agonist is an arylpiperazine compound, such as a piperazinylpyrazine compound.
- 15. The pharmaceutical composition according to claim 3, wherein the 5-HT6 receptor antagonist is selected from azepinoindoles, such as a arylsulfone-substituted hexahydroazepinoindoles, and arylsulfonylindoles.
- 16. The pharmaceutical composition according to claim 1, wherein the 5-HT2C receptor agonist has a selectivity for the 5-HT2C receptor of at least about 20 relative to the 5-HT2A receptor, the 5-HT2B receptor, and the 5-HT6 receptor, respectively.
- 17. The pharmaceutical composition according to claim 1 or 2, wherein the 5-HT6 receptor antagonist has a selectivity for the 5-HT6 receptor of at least about 20 relative to the 5-HT2A receptor, the 5-HT2B receptor and the 5-HT2C receptor, respectively.
- 18. The pharmaceutical composition according to claim 16, wherein the 5-HT2C receptor agonist is an arylpiperazine compound, such as a piperazinylpyrazine compound.
- 19. The pharmaceutical composition according to claim 17, wherein the 5-HT6 receptor antagonist is selected from azepinoindoles, such as arylsulfone-substituted hexahydroazepinoindoles, and arylsulfonylindoles.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0002754 |
Jul 2000 |
SE |
|
Parent Case Info
This application claims the benefit of provisional application 60/222,283 filed Aug. 1, 2000.
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO 9827081 |
Jun 1998 |
WO |
WO 9965906 |
Dec 1999 |
WO |
WO 0012510 |
Mar 2000 |
WO |
Non-Patent Literature Citations (2)
Entry |
Dourish, “Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity?,” Obesity Research, 3(Supp. 4):449S-462S, Nov. 1995. |
Kordik et al., “Pharmacological Treatment of Obesity: Therapeutic Strategies,” Journal of Medicinal Chemistry, 42(2):181-201, Jan. 28, 1999. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/222283 |
Aug 2000 |
US |